Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trialBruce Cree, Eliezer Katz, Jeffrey L. Bennett et al.|The Lancet|2019Cited by 722
A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunityJodi L. Karnell, Jörn Drappa, Thomas Thisted et al.|Science Translational Medicine|2019Cited by 98
Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum DisorderRomain Marignier, Bruce Cree, Jeffrey L. Bennett et al.|Neurology Neuroimmunology & Neuroinflammation|2021Cited by 42
AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorderRomain Marignier, Bruce Cree, Daniel Cimbora et al.|Multiple Sclerosis and Related Disorders|2021Cited by 37